Skip to main content

Table 2 Primary and secondary outcome measure responses at week 2 and week 4 of corticosteroid treatment

From: Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study

Parameter Axial psoriatic arthritis Ankylosing spondylitis Control P value,
AxPsA vs. AS
Mean difference from baseline to week 2
 ASDAS 1.43 ± 0.39 1.03 ± 0.30 0.81 ± 0.26 0.004
 VAS 2.46 ± 0.91 1.66 ± 1.1 1.0 ± 0.94 0.003
 ASQoL 3.80 ± 1.82 2.4 ± 1.72 0.7 ± 0.67 <0.001
 BASFI 2.38 ± 0.68 0.95 ± 0.91 0.44 ± 0.41 <0.001
 BASDAI 1.93 ± 0.56 1.13 ± 0.33 0.84 ± 0.24 <0.001
Mean difference from baseline to week 4
 ASDAS 1.09 ± 0.32 0.77 ± 0.27 0.73 ± 0.24 0.007
 VAS 2.00 ± 0.92 1.33 ± 0.72 1.30 ± 0.82 0.054
 ASQoL 3.53 ± 1.35 2.26 ± 1.53 0.70 ± 0.67 <0.001
 BASFI 1.76 ± 0.82 0.78 ± 0.63 0.48 ± 0.24 <0.001
 BASDAI 1.57 ± 0.49 0.85 ± 0.45 0.62 ± 0.23 <0.001
  1. Data are presented as (mean ± SD)
  2. AxPsA axial psoriatic arthritis, AS ankylosing spondylits, VAS visual analogue scale, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score